Active, not recruitingPhase 3NCT04195750
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Studying Chromophobe renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Belzutifan(drug)
- Enrollment
- 755 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- University of Alabama - Birmingham ( Site 1538), Birmingham, Alabama, United States
- University of California San Diego Moores Cancer Center ( Site 1546), La Jolla, California, United States
- St Joseph Heritage Healthcare ( Site 1531), Santa Rosa, California, United States
- University Of Colorado ( Site 1540), Aurora, Colorado, United States
- UCHealth Highlands Ranch Hospital ( Site 1560), Highlands Ranch, Colorado, United States
- Sibley Memorial Hospital ( Site 1559), Washington D.C., District of Columbia, United States
- Northwest Georgia Oncology Centers PC ( Site 1520), Marietta, Georgia, United States
- The University of Chicago Medical Center ( Site 1539), Chicago, Illinois, United States
- Ochsner Medical Center ( Site 1522), New Orleans, Louisiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514), Baltimore, Maryland, United States
- Massachusetts General Hospital ( Site 1558), Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center ( Site 1501), Boston, Massachusetts, United States
- Dana Farber Cancer Institute ( Site 1505), Boston, Massachusetts, United States
- Henry Ford Cancer Center ( Site 1511), Detroit, Michigan, United States
- Hattiesburg Clinic ( Site 1509), Hattiesburg, Mississippi, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04195750 on ClinicalTrials.govOther trials for Chromophobe renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07485114Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 InhibitorsDaniel Keizman
- RECRUITINGPHASE3NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07233252Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerTianjin Medical University Second Hospital
- RECRUITINGNANCT07171190Targeted Abdominal CT in Conjunction With Lung Cancer ScreeningUniversity of Cambridge
- RECRUITINGPHASE2NCT07050771Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer SurgeryThe Methodist Hospital Research Institute
- RECRUITINGPHASE2NCT06642220Ablative Radioembolization of Renal Cell Carcinoma TrialDerek W. Cool
- RECRUITINGNCT06889974Timing of Renal Replacement Therapy Initiation in Tumor Lysis SyndromeUniversity Hospital, Bordeaux
- ENROLLING BY INVITATIONNCT07307157Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewHarvard Medical School (HMS and HSDM)